Dr. Kapil Bharti’s lab at the National Eye Institute recently started the first U.S. phase I/IIa trial to test autologous iPSC-derived RPE patch in AMD patients. Currently, he is co-developing a dual RPE/photoreceptor cell therapy with Opsis Therapeutics. He has given several keynote lectures and won several awards for his revolutionary work on developing ocular cell-therapies. He serves on the advisory board (pro bono) of several companies and patient-advocacy groups. His current work as a Senior Investigator at NEI involves understanding the mechanism of retinal degenerative diseases using induced pluripotent stem cell derived eye cells and tissues and developing cell-based and drug-based therapies for such diseases. He is the Director of the NEI Intramural Research Program where he oversees 21 research labs and 6 core facilities.

Dr. Bharti is also a Macular Degeneration Research grantee. Learn more about his funded work here: Engineered Eye Tissue Models to Analyze Mechanisms of Age-related Vision Loss.

#Macular #MacularDegeneration #Retina #LowVision